Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Australia
University of Alberta, Edmonton, Canada.
mBio. 2020 Oct 23;11(5):e02617-20. doi: 10.1128/mBio.02617-20.
The existence and nature of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are currently unknown; however, neutralizing antibodies are thought to play the major role and data from studying other coronaviruses suggest that partial clinical immunity lasting up to 1 year will occur postinfection. We show how immunity, depending on its durability, may work with current social practices to limit the spread of the virus. We further show that a vaccine that is 50% effective and taken by 50% of the population will prevent further loss of life, providing that social distancing is still practiced and that immunity does not wane quickly. The ability of our society to function effectively moving forward will depend on how the spread of the SARS-CoV-2 virus is contained. Immunity to the virus will be critical to this equation.
目前尚不清楚针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的免疫力的存在和性质;然而,据认为中和抗体起着主要作用,并且对其他冠状病毒的研究数据表明,感染后会产生持续长达 1 年的部分临床免疫力。我们展示了免疫力如何根据其持久性与当前的社会实践相结合来限制病毒的传播。我们进一步表明,在继续实行社交距离并且免疫力不会迅速减弱的情况下,如果接种 50%的人口且有效率为 50%的疫苗,将防止更多的生命损失。我们的社会能否有效地向前发展,将取决于如何控制 SARS-CoV-2 病毒的传播。对该病毒的免疫力将是这一方程式的关键。